BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 33620107)

  • 1. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).
    Pallotto C; Suardi LR; Gabbuti A; Esperti S; Mecocci L; Blanc P
    J Med Virol; 2021 May; 93(5):2631-2634. PubMed ID: 33620107
    [No Abstract]   [Full Text] [Related]  

  • 2. Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.
    Attena E; Albani S; Maraolo AE; Mollica M; De Rosa A; Pisapia R; Fiorentino G; Parrella R; Severino S; Russo V
    Circ Arrhythm Electrophysiol; 2021 Jul; 14(7):e009811. PubMed ID: 34182791
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
    Singh A; Kamath A
    Expert Opin Drug Saf; 2021 Dec; 20(12):1559-1564. PubMed ID: 34328807
    [No Abstract]   [Full Text] [Related]  

  • 4. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.
    McCoy JA; Short WR; Srinivas SK; Levine LD; Hirshberg A
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100164. PubMed ID: 32838267
    [No Abstract]   [Full Text] [Related]  

  • 5. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
    Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
    Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
    Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
    Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
    Trials; 2020 May; 21(1):422. PubMed ID: 32448345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET 1: The role of remdesivir in COVID-19 infection.
    Baombe JP
    Emerg Med J; 2020 Aug; 37(8):522-523. PubMed ID: 32753375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.
    Chang HY; Hsu CC; Hu LF; Chou CY; Chang YL; Lu CC; Chang LJ
    Ann Med; 2024 Dec; 56(1):2361843. PubMed ID: 38830017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury in remdesivir-treated COVID-19 patients.
    Zampino R; Mele F; Florio LL; Bertolino L; Andini R; Galdo M; De Rosa R; Corcione A; Durante-Mangoni E
    Hepatol Int; 2020 Sep; 14(5):881-883. PubMed ID: 32725454
    [No Abstract]   [Full Text] [Related]  

  • 12. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.
    Day LB; Abdel-Qadir H; Fralick M
    CMAJ; 2021 Apr; 193(17):E612-E615. PubMed ID: 33903133
    [No Abstract]   [Full Text] [Related]  

  • 13. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
    Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
    J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
    [No Abstract]   [Full Text] [Related]  

  • 14. Audio Interview: New Data on Remdesivir in Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2020 May; 382(22):e94. PubMed ID: 32459948
    [No Abstract]   [Full Text] [Related]  

  • 15. Remdesivir (Veklury) for COVID-19.
    Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.
    Schreiber A; Bauzon JS; Batra K; Mohammed S; Lee K; Houshmand N; Pham U; Cosme C; Inciong K; Al-Taweel O; Nasser K; Rana J; Sossou C; Go A; Hawwass D; Diep J; Ahsan CH
    Clin Drug Investig; 2022 Sep; 42(9):763-774. PubMed ID: 35978159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review.
    Yang CJ; Wei YJ; Chang HL; Chang PY; Tsai CC; Chen YH; Hsueh PR
    J Microbiol Immunol Infect; 2021 Feb; 54(1):27-36. PubMed ID: 33060041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case Report for Severe COVID-19 in a 9-Year-Old Child Treated with Remdesivir and Dexamethasone.
    Jo YH; Hwang Y; Choi SH
    J Korean Med Sci; 2021 Jul; 36(29):e203. PubMed ID: 34313036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series.
    Carothers C; Birrer K; Vo M
    Pharmacotherapy; 2020 Nov; 40(11):1166-1171. PubMed ID: 33006138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
    Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
    CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.